In a recent webcast, Dr. Ronald Korn, Founder and CMO at Imaging Endpoints and Kelie Williams Luby, VP Clinical Trials Software at Mint Medical, presented an integrated, comprehensive analysis using the mint Lesion™ platform for a seamless evaluation of COVID-19 patients and trials.
Together they highlighted the need for expert image analysis and the urgent need for organized data collection, encompassing the multi-dimensional data of imaging, laboratory, clinical, and demographics for COVID-19.
While imaging should not be used as a screening tool for unselected populations, it supports a comprehensive approach which can be applied in both clinical care and clinical trials. The mint Lesion™ platform integrates this multi-dimensional data creating a digital signature for the patient while enabling data quality, integrity, and traceability acquired in a high-trust environment.
-
65 minute(s)
Radiologic Analysis of COVID-19 Infection
Related Resources
Related Resources
University of Miami & Nova Souteastern University: Study shows feasibility of radiomics and T2 mapping as novel imaging biomarkers of activity in superficial fibromatosis
A retrospective study [1] conducted by researchers at University of Miami Miller School of Medicine and Nova Southeastern University investigated…
Quantitative Tumorbegleitung und ihre Einbettung in holistische Befundstrukturen (Only in German)
Wie können die Ergebnisse software-unterstützter Tumorbeurteilung gewinnbringend in die Routine-Kommunikation mit den klinischen Zuweisern und…
A Future Vision of Data-Driven Radiology | Integrated Diagnostics
Medical imaging contributes key diagnostic information to the evidence-based therapeutic decision process. The transformation of radiological images…